公开(公告)号：US20190008872A1

公开(公告)日：2019-01-10

申请号：US15644945

申请日：2017-07-10

Applicant: Macau University of Science and Technology

Inventor： Liang Liu ,  Kam Wai Wong ,  Yuen Kwan Law ,  Cong Ling Qiu

IPC: A61K31/56 ,  A61K31/519 ,  A61K31/573 ,  A61K31/165

Abstract: A method for treating a subject suffering from refractory rheumatoid arthritis includes the step of administering an effective amount of a quinonemethide triterpenoid or a pharmaceutically tolerable salt, solvate or anhydrate thereof to the subject. Also is a method for inducing autophagy in a synovial fibroblast, and a method of inducing calcium mobilization in a synovial fibroblast. Further a pharmaceutical composition includes an effective dose of a quinonemethide triterpenoid and an anti-arthritis compound. The quinonemethide triterpenoid is suitable to treat refractory rheumatoid arthritis (RA) in particular ABC-protein-dependent RA and apoptosis-deficient RA. The quinonemethide triterpenoid also possesses significant inhibitory effects on the growth of synovial fibroblasts, in particular modulating the calcium homeostasis in multidrug-resistant rheumatoid arthritis synovial fibroblasts.

公开(公告)号：US09974766B2

公开(公告)日：2018-05-22

申请号：US14953860

申请日：2015-11-30

Applicant: Macau University of Science and Technology

Inventor： Kam Wai Wong ,  Yuen Kwan Law ,  Thomas Efferth ,  Onat Kadioglu ,  Liang Liu

IPC: A61K31/352 ,  A61K31/704 ,  A61K31/337

CPC classification number: A61K31/352 ,  A61K31/337 ,  A61K31/704 ,  A61K2300/00

Abstract: Prenylated isoflavones are suitable to specifically inhibit P-glycoprotein in multidrug-resistant cancer cells leading to an accumulation of cytotoxic compounds or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity specifically towards multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds towards which the cells are resistant.Also in accordance with the present invention is a method for specifically targeting cancer cells with multidrug-resistance as well as a method of potentiating the activity of a chemotherapeutic compound in multidrug-resistant cancer cells. In a further aspect, a kit including a prenylated isoflavone and a chemotherapeutic compound is provided.

公开(公告)号：US20180050045A1

公开(公告)日：2018-02-22

申请号：US15632738

申请日：2017-06-26

Applicant: Macau University of Science and Technology

Inventor： Kam Wai Wong ,  Yuen Kwan Law ,  Man Chung Wong

IPC: A61K31/555

CPC classification number: A61K31/28 ,  A61K31/555 ,  A61K45/06

Abstract: A method for inhibiting the expression and/or functional activity of an ABC transporter protein in a subject suffering from a disorder associated with an overexpression of the ABC transporter protein includes administrating a cobalt-polypyridyl complex to the subject. A method for inhibiting the expression and/or functional activity of an ABC transporter in cells includes contacting the cells with an effective amount of the cobalt-polypyridyl complex.

公开(公告)号：US09561223B2

公开(公告)日：2017-02-07

申请号：US14985420

申请日：2015-12-31

Applicant: Macau University of Science and Technology

Inventor： Kam Wai Wong ,  Yuen Kwan Law ,  Liang Liu ,  Jingrong Wang

IPC: A61K31/4725 ,  A61K31/4745 ,  A61K31/4748

CPC classification number: A61K31/4745 ,  A61K31/4725 ,  A61K31/4748

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

公开(公告)号：US10688105B2

公开(公告)日：2020-06-23

申请号：US15644945

申请日：2017-07-10

Applicant: Macau University of Science and Technology

Inventor： Liang Liu ,  Kam Wai Wong ,  Yuen Kwan Law ,  Cong Ling Qiu

IPC: A61K31/185 ,  A61K31/495 ,  A61K31/56 ,  A61K31/519 ,  A61K31/573 ,  A61K31/165 ,  A61K31/42 ,  A61K45/06 ,  A61K31/635 ,  A61K31/19 ,  A61K39/00 ,  A61K31/365

Abstract: A method for treating a subject suffering from refractory rheumatoid arthritis includes the step of administering an effective amount of a quinonemethide triterpenoid or a pharmaceutically tolerable salt, solvate or anhydrate thereof to the subject. Also is a method for inducing autophagy in a synovial fibroblast, and a method of inducing calcium mobilization in a synovial fibroblast. Further a pharmaceutical composition includes an effective dose of a quinonemethide triterpenoid and an anti-arthritis compound. The quinonemethide triterpenoid is suitable to treat refractory rheumatoid arthritis (RA) in particular ABC-protein-dependent RA and apoptosis-deficient RA. The quinonemethide triterpenoid also possesses significant inhibitory effects on the growth of synovial fibroblasts, in particular modulating the calcium homeostasis in multidrug-resistant rheumatoid arthritis synovial fibroblasts.

公开(公告)号：US10322097B2

公开(公告)日：2019-06-18

申请号：US14971153

申请日：2015-12-16

Applicant: Macau University of Science and Technology

Inventor： Kam Wai Wong ,  Yuen Kwan Law ,  Thomas Efferth ,  Su-Wei Xu ,  Sami Hamdoun ,  Liang Liu

IPC: A61K31/19 ,  A61K31/337 ,  A61K31/553 ,  A61K31/704 ,  A61K31/7048 ,  A61K33/24

Abstract: A quinonemethide triterpenoid is administered to subjects with multidrug-resistant cancer, in particular a cancer with enhanced expression and/or functional activity of ABC transporter proteins such as P-glycoprotein and/or an apoptosis-deficient, in particular p53-, Bax- or Bak-deficient, cancer, i.e. specific subgroups of subjects with cancer. The quinonemethide triterpenoid is suitable to treat cancer allowing for an accumulation of cytotoxic or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity towards the multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds. Methods for specifically targeting cancer cells with multidrug-resistance and methods for potentiating the activity of a chemotherapeutic compound in those cancer cells are also disclosed. A kit including a quinonemethide triterpenoid and a chemotherapeutic compound is also provided.

公开(公告)号：US09561221B2

公开(公告)日：2017-02-07

申请号：US14985417

申请日：2015-12-31

Applicant: Macau University of Science and Technology

Inventor： Kam Wai Wong ,  Yuen Kwan Law ,  Liang Liu ,  Jingrong Wang

IPC: A61K31/4725 ,  A61K31/4745 ,  A61K31/4748

CPC classification number: A61K31/4745 ,  A61K31/4725 ,  A61K31/4748

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

公开(公告)号：US10369127B2

公开(公告)日：2019-08-06

申请号：US15632738

申请日：2017-06-26

Applicant: Macau University of Science and Technology

Inventor： Kam Wai Wong ,  Yuen Kwan Law ,  Man Chung Wong

IPC: A61K31/28 ,  A61K31/555 ,  A61K45/06

Abstract: A method for inhibiting the expression and/or functional activity of an ABC transporter protein in a subject suffering from a disorder associated with an overexpression of the ABC transporter protein includes administrating a cobalt-polypyridyl complex to the subject. A method for inhibiting the expression and/or functional activity of an ABC transporter in cells includes contacting the cells with an effective amount of the cobalt-polypyridyl complex.

公开(公告)号：US09675608B2

公开(公告)日：2017-06-13

申请号：US14925962

申请日：2015-10-28

Applicant: Macau University of Science and Technology

Inventor： Kam Wai Wong ,  Yuen Kwan Law ,  Liang Liu

IPC: A61K31/44 ,  A61K31/4745

CPC classification number: A61K31/4745

Abstract: The present invention discloses a method of treating cancer and/or multidrug-resistant cancer, comprising administering an effective amount of hernandezine or thalidezine. A pharmaceutical composition comprising hernandezine or thalidezine admixed with a pharmaceutical carrier for treating cancers and/or multidrug-resistant cancer is also disclosed.

公开(公告)号：US09561222B2

公开(公告)日：2017-02-07

申请号：US14985419

申请日：2015-12-31

Applicant: Macau University of Science and Technology

Inventor： Kam Wai Wong ,  Yuen Kwan Law ,  Liang Liu ,  Jingrong Wang

IPC: A61K31/4725 ,  A61K31/4745 ,  A61K31/4748

CPC classification number: A61K31/4745 ,  A61K31/4725 ,  A61K31/4748

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.